Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
You may also be interested in...
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
Although it surprised many in India to have Fujifilm's name associated with generic drugs, its penchant to explore the Japanese market coincides with the Japanese government's mission to encourage use of generic substitutes in Japan to drive costs down.